Forty Seven Inc

Overview

Forty Seven Inc (Forty Seven), formerly CD47 Sciences Inc is a clinical-stage immuno-oncology company that focuses on the development of therapies to treat cancer. The company’s lead molecule Hu5F9-G4 is a monoclonal antibody that is used against the CD47 receptor. Its monoclonal antibody is evaluated in four phase 1 clinical studies in patients with solid tumors or cutaneous T-cell lymphoma, acute myeloid leukemia, non-Hodgkin’s lymphoma, myelodysplastic syndrome and colorectal carcinoma across the US and the UK. The company partners with biotechnology and pharmaceutical companies. Forty Seven is headquartered in Menlo Park, California, the US.
Key Stats
Address
1490 Obrien Dr Ste A, Menlo Park, California
Headquarters

United States of America

Contact

1 650 3524150

No of Employees

68

Industry

Pharmaceuticals and Healthcare

Peer Comparison

Key Parameters Forty Seven IncLegend Biotech CorpAmbrx Biopharma IncImmunitas Therapeutics Inc
Key Information
Headquarters United States of America United States of America United States of America United States of America
Headquarter City Menlo Park Somerset La Jolla Waltham
Headquarter State/Province California New Jersey California Massachusetts
No. of Employees 68 882 70 -
Entity Type Private Public Public Private

Products & Services

Forty Seven is an immuno-oncology company. Key products offered by the company include the following:

Products
  • Pipeline 5F9 for the treatment of solid tumors and AML MDS
  • 5F9 + Rituximab for the treatment of B-Cell NHL
  • 5F9 + Cetuximab for the treatment of Colorectal Cancer
  • Vitae Eget Libero
  • Vitae Eget Libero

Employees

Name Position Board Since Age Biography
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.

History

Year Event Description
2020 Ownership Changes In April, the company was acquired by Gilead Sciences, Inc for US$4.9 billion.
2020 Contracts/Agreements In March, the company entered into a partnership with Rocket Pharmaceuticals to evaluate the combination…
2019 Contracts/Agreements In November, the company and bluebird bio entered into a collaboration to pursue clinical proof-of-concept…
2019 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam
2018 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam
2018 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam

Deals

Number of Deals
Deal Value (US$ m)

Latest Deals

Announced Date Headline Deal Type Acquirers / Investors / Surviving Entity Issuer / partner / Target
16 Jul 2019 Forty Seven Raises USD86.3 Million in Public Offering of Shares Equity Offering Forty Seven Inc
10 May 2019 Forty Seven and Acerta Pharma Enter into Agreement Partnership Forty Seven Inc; Acerta Pharma BV
30 Jun 2018 Forty Seven Acquires Assets from BliNK Biomedical Asset Transaction Forty Seven Inc BliNK Biomedical SAS
27 Jun 2018 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
11 Jan 2018 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
11 Jan 2018 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit

Jobs Overview

9

Active Jobs

0

Posted

0

Closed

Job Trends

Latest Jobs

Job title Company Country
Biospecimen/ Sample Management Associate Forty Seven Inc United States
Associate Medical Director/Medical Director Forty Seven Inc United States
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar